Clearside Biomedical, Inc. (CLSDQ): restructuring charge — Clearside explores strategic alternatives; all employees terminated, R&D paused

Clearside Biomedical, Inc.

All employees, including CEO, CFO, CMO, terminated effective July 18, 2025, transition to consulting roles.
Estimated $3.4M severance charges in Q3 2025; internal R&D programs paused.
Retained Piper Sandler to evaluate sale, license, merger, or other strategic transactions.
No agreement reached; no timetable set; no assurance any transaction will occur.
CLS-AX Phase 3-ready in wet AMD; SCS Microinjector platform with five licensing partners.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Clearside Biomedical, Inc. announced a restructuring with charges of approximately $3.4 million for severance and other employee termination-related costs affecting the Company (all Clearside employees).

Type: restructuring
Charge: approximately $3.4 million for severance and other employee termination-related costs
Affected area: the Company
Headcount: all Clearside employees

Exact text from the filing

On July 17, 2025, Clearside Biomedical, Inc. (the “ Company ”) announced that it is exploring strategic alternatives to enhance shareholder value, and that in connection with such process and in order to extend the Company’s resources, the Company is implementing a plan pursuant to which all Clearside employees will have their employment with the Company terminated and will transition into consulting roles with the Company. The reduction in force is expected to be completed during the third quarter of 2025. The Company estimates that it will incur charges of approximately $3.4 million for severance and other employee termination-related costs in the third quarter of 2025.

View on SEC.gov

3 restructurings & charges filed in the last 30 days. Browse all restructurings & charges →

Clearside Biomedical, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-25-096438

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.